Combination Therapy Extends Survival in Patients with Severe Heart Disease
A groundbreaking study shows that combining valve replacement with targeted drug therapy significantly improves survival in patients with severe heart conditions, including aortic stenosis and cardiac amyloidosis.
Recent research conducted by an international consortium led by MedUni Vienna and University College London has revealed promising advancements in treating severe heart conditions, particularly in patients suffering from both aortic stenosis and cardiac amyloidosis. Traditionally, treatments focused solely on mechanical interventions such as valve replacement, leaving the amyloid deposits in the heart muscle often untreated. However, the new study demonstrates that a combined approach—integrating aortic valve replacement with targeted drug therapy for amyloidosis—significantly improves patient survival rates.
The study analyzed data from 226 patients across ten countries, all diagnosed with both aortic stenosis and cardiac amyloidosis. Aortic stenosis involves the narrowing of the heart valve, obstructing blood flow from the heart's left ventricle into the circulation. Cardiac amyloidosis occurs when misfolded proteins deposit in the heart tissue, impairing its function. Both conditions predominantly affect older adults and frequently coexist.
Importantly, the research shows that patients receiving both valve replacement and tafamidis, a drug used to treat amyloidosis, had notably better survival outcomes. In fact, those who underwent both treatments displayed long-term survival rates similar to patients with aortic stenosis alone without amyloidosis. This underscores the importance of comprehensive treatment strategies.
The findings advocate for routine screening for amyloidosis in patients with severe aortic stenosis. Recognizing the co-occurrence enables healthcare providers to administer targeted therapies that can prolong life and improve quality of life. Early detection and combined treatment are crucial in managing these complex, age-related cardiac diseases.
Overall, this research highlights the potential to change clinical practice by emphasizing the importance of diagnosing and treating both conditions concurrently, paving the way for better patient outcomes in severe heart disease cases.
Source: https://medicalxpress.com/news/2025-06-combination-therapy-prolong-life-severe.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Gwada-negative: The Rarest Blood Group on Earth
French scientists have discovered the world's rarest blood group, Gwada-negative, found in a woman from Guadeloupe. This groundbreaking finding highlights the complexity of human blood systems and the potential for future personalized transfusion solutions.
Innovative Approach to Fabricate Custom 3D Neural Chips Using 3D Printing and Capillary Action
KAIST scientists have developed a revolutionary method to create customizable 3D neural chips using 3D printing and capillary action, advancing brain research and neural engineering.
How Menopause Affects Women's Voices and Its Significance
New research reveals how hormonal changes during menopause can alter women's voices, emphasizing the importance of awareness and targeted treatments for vocal health.
